Save up to 85% on Cancer Medicines!
Xovoltib 30mg Tablet

Xovoltib 30mg Tablet

Prescription requiredRx Required

Salt Composition: Afatinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

28 Tablet

About The Product

Lung Cancer

Description

  • Xovoltib 30mg Tablet is an anticancer medicine. It is prescribed to treat non-small cell lung cancer in the adult patients who have certain mutations of epidermal growth factor receptor (EGFR).
  • It contains Afatinib as an active ingredient that works by inhibiting the enzyme receptors to inhibit the growth and multiplication of cancer cells. Take it as prescribed by the doctor at the same time each day.


Uses

  • Non-small cell lung cancer

Side Effects

Like any other anticancer medicine, Xovoltib 30mg Tablet   also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:

  • Loose bowels
  • Blood in the pee
  • Change in the measure of pee
  • Quick or sporadic heartbeat
  • Mouth aggravation
  • Nail issues
  • Shortness of breath
  • Unordinary weight gain
  • Swelling of the hands, arms or legs
  • Inconvenience urinating

Seek medical attention in case of any unusual or severe side effects immediately.

How To Use

  • Xovoltib Tablet is an anticancer medicine available in 20 mg, 30 mg, & 40 mg dosage. Doctor determines the exact dose and duration of the medicine as per patient's health condition. Do not crush or break the tablet.
  • In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the Afatinib dose without informing your doctor.

How It Works

Xovoltib 30mg Tablet is an anticancer medicine that contains Afatinib as an active ingredient. It works by blocking the action of a protein known as epidermal growth factor receptor (EGFR) that is responsible for the growth and multiplication of certain cancer cells.

Results in slowing down the progression of non-small cell lung cancer in patients with specific EGFR gene mutations.

Safety Advice

Alcohol

Avoid the consumption of alcohol while taking Xovoltib 30mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.

Pregnancy

Do not take Xovoltib 30mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.

Breast Feeding

Breastfeeding women should discuss the potential risks and benefits of the Xovoltib 30mg Tablet with their healthcare provider before starting treatment.

Driving

Xovoltib 30mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.

Kidney

Share your medical history with the doctor before starting the Xovoltib 30mg Tablet. Do not take it without consulting a doctor if you have any kidney related issue.

Liver

Share your medical history with the doctor before starting the Xovoltib 30mg Tablet. Do not take it without consulting a doctor if you have any liver related issue.

FAQs

Xovoltib 30mg Tablet is an anticancer tablet that is primarily used in the treatment of non-small cell lung cancers.

​ ​

Reference

  • Yang, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S. K., Schuler, M., ... & Wu, Y. L. (2015). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The lancet oncology, 16(7), 830-838. https://pubmed.ncbi.nlm.nih.gov/26051236/
  • Helena, A. Y., & Pao, W. (2013). Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer. Nature reviews Clinical oncology, 10(10), 551. https://pubmed.ncbi.nlm.nih.gov/23959269/
  • Giordano, P., Manzo, A., Montanino, A., Costanzo, R., Sandomenico, C., Piccirillo, M. C., ... & Morabito, A. (2016). Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. Critical reviews in oncology/hematology, 97, 143-151. https://pubmed.ncbi.nlm.nih.gov/26318094/
  • Schuler, M., Yang, J. H., Park, K., Kim, J. H., Bennouna, J., Chen, Y. M., ... & Popovych, O. (2016). Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 27(3), 417-423. https://pmc.ncbi.nlm.nih.gov/articles/PMC4769992/
  • Dungo, R. T., & Keating, G. M. (2013). Afatinib: first global approval. Drugs, 73(13), 1503-1515. https://pubmed.ncbi.nlm.nih.gov/23982599/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026